{{scheme.chgp}}%
{{scheme.chgp}}%
No Matches Found
{{scheme.chgp}}%
No Matches Found
No Matches Found
Is Sonoma Pharmaceuticals, Inc. technically bullish or bearish?
As of June 17, 2025, the trend is mildly bullish with supportive indicators like the MACD and OBV, but caution is advised due to bearish signals from the Bollinger Bands on the monthly timeframe.
Who are in the management team of Sonoma Pharmaceuticals, Inc.?
As of March 2022, the management team of Sonoma Pharmaceuticals, Inc. includes Lead Independent Director Jerry McLaughlin, Independent Directors Sharon Barbari, Jay Birnbaum, and Philippe Weigerstorfer, who oversee the company's strategic direction and governance.
What does Sonoma Pharmaceuticals, Inc. do?
Sonoma Pharmaceuticals, Inc. is a specialty pharmaceutical company focused on developing and marketing solutions for dermatological conditions and advanced tissue care. As of December 2024, it reported net sales of $4 million and a net loss of $1 million, with a market cap of $4.77 million.
How big is Sonoma Pharmaceuticals, Inc.?
As of Jun 18, Sonoma Pharmaceuticals, Inc. has a market capitalization of 4.77 million, with net sales of 13.97 million and a net profit of -3.75 million over the latest four quarters. The company reported shareholder's funds of 6.14 million and total assets of 14.89 million as of Mar 24.
{{list.post_title}}
{{list.post_excerpt}}
{{list.post_title}}
{{list.post_excerpt}}
